Detalhe da pesquisa
1.
An in vitro toolbox to accelerate anti-malarial drug discovery and development.
Malar J
; 19(1): 1, 2020 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31898492
2.
Development and application of a PBPK modeling strategy to support antimalarial drug development.
CPT Pharmacometrics Syst Pharmacol
; 12(9): 1335-1346, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37587640
3.
The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.
Xenobiotica
; 42(1): 28-45, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22077101
4.
Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms.
Xenobiotica
; 42(1): 57-74, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21992032
5.
Application of PBPK modelling in drug discovery and development at Pfizer.
Xenobiotica
; 42(1): 94-106, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22035569
6.
Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects.
Br J Clin Pharmacol
; 72(2): 263-9, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21545485
7.
Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.
Drug Metab Dispos
; 37(8): 1658-66, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19406954
8.
Maraviroc: in vitro assessment of drug-drug interaction potential.
Br J Clin Pharmacol
; 66(4): 498-507, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18647303
9.
Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction.
Br J Clin Pharmacol
; 65(5): 680-92, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18279465
10.
Risk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach.
Clin Pharmacol Ther
; 104(6): 1229-1239, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29637542
11.
Substrate SARs in human P450s.
Drug Discov Today
; 7(17): 918-25, 2002 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12546935
12.
Compound lipophilicity for substrate binding to human P450s in drug metabolism.
Drug Discov Today
; 9(12): 530-7, 2004 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15183161
13.
Induction of cytochromes P450.
Curr Top Med Chem
; 4(16): 1745-66, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-15579106
14.
Substrates of human cytochromes P450 from families CYP1 and CYP2: analysis of enzyme selectivity and metabolism.
Drug Metabol Drug Interact
; 20(3): 111-42, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-15508429
15.
Investigation of enzyme selectivity in the human CYP2C subfamily: homology modelling of CYP2C8, CYP2C9 and CYP2C19 from the CYP2C5 crystallographic template.
Drug Metabol Drug Interact
; 19(4): 257-85, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-14768974
16.
Molecular modelling of CYP2B6 based on homology with the CYP2C5 crystal structure: analysis of enzyme-substrate interactions.
Drug Metabol Drug Interact
; 19(2): 115-35, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-12751910
17.
A molecular model of CYP2D6 constructed by homology with the CYP2C5 crystallographic template: investigation of enzyme-substrate interactions.
Drug Metabol Drug Interact
; 19(3): 189-210, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-14682610
18.
Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling.
Clin Pharmacokinet
; 50(5): 331-47, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21456633
19.
An evaluation of ondansetron binding interactions with human cytochrome P450 enzymes CYP3A4 and CYP2D6.
Drug Metab Lett
; 4(1): 25-30, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20201779
20.
The importance of predictive ADME simulation.
Drug Discov Today
; 7(14): 755-6, 2002 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12547029